Enterprise Value
76.32B
Cash
8.71B
Avg Qtr Burn
N/A
Short % of Float
0.87%
Insider Ownership
0.00%
Institutional Own.
10.35%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Dupixent Details Eosinophilic Esophagitis | Approved Quarterly sales | |
ALTUVIIIO™ (Efanesoctocog alfa) Details Hemophilia | Approved Quarterly sales | |
Beyfortus™ (Nirsevimab- alip) Details Respiratory syncytial virus | Approved Quarterly sales | |
TZIELD™ (PRV-031) (Teplizumab) Details Type 1 diabetes, Diabetes | Approved Quarterly sales | |
Fitusiran Details Hemophilia | BLA Submission | |
Tolebrutinib Details Multiple sclerosis, Autoimmune disease | BLA Submission | |
Amlitelimab Details Atopic dermatitis | Phase 3 Data readout | |
ExPEC9V vaccine Details Invasive Extraintestinal Pathogenic Escherichia Coli Disease | Phase 3 Data readout | |
Dupixent Details Chronic spontaneous urticaria | Phase 3 Data readout | |
Tzield (Teplizumab) Details Type 1 diabetes, Diabetes | Phase 3 Update | |
Frexalimab Details Autoimmune disease, Multiple sclerosis | Phase 3 Update | |
Sarclisa® Details Multiple myeloma, Cancer | Phase 3 Update | |
Ordesekimab (PRV-015) (anti-IL-15) Details Celiac disease, Immune Disorders | Phase 2b Data readout | |
PRV-3279 Details Systemic lupus erythematosus, Autoimmune disease | Phase 2a Data readout |